



Maine Department of Health and Human Services
Maine Center for Disease Control and Prevention
11 State House Station
Augusta, Maine 04333-0011
Tel: (207) 287-8016; Fax (207) 287-9058
TTY Users: Dial 711 (Maine Relay)

Maine Health Alert Network (HAN) System

PUBLIC HEALTH ADVISORY

To: All Health Care
From: Dr. Isaac Benowitz, State Epidemiologist
Subject: U.S. CDC: Increase in Invasive Serogroup Y Meningococcal Disease in the United States
Date / Time: Wednesday, April 3, 2024, at 4:20PM
Pages: 4
Priority: Normal
Message ID: 2024PHADV006

Please take a moment to review this information on invasive serogroup Y meningococcal disease in the U.S.

U.S. CDC is reporting an increase in invasive meningococcal disease in the U.S. in 2024, mainly attributable to *Neisseria meningitidis* serogroup Y. Most cases involve a single sequence type, ST-1466. Most of the patients are between 30–60 years old, are Black or African American, or are living with HIV. In addition, most cases caused by this strain had a clinical presentation other than meningitis, such as bacteremia and septic arthritis.

Vaccines against serogroups A, C, W, Y (MenACWY) and serogroup B (MenB) are available in the United States. [MenACWY vaccines are routinely recommended](#) for adolescents and for people with other risk factors or underlying medical conditions, including HIV.

Maine has reported 21 cases of meningococcal disease over the last 10 years. Of these 21 cases, 2 were serogroup Y, one in 2014 and one in January 2024.

Meningococcal disease is immediately reportable to Maine CDC upon recognition or strong suspicion of disease. To contact Maine CDC, please call the 24/7 disease reporting number at 800-821-5821.

Specimens for testing should be collected soon after onset of illness, preferably before the start of treatment.

The gold standard for diagnosis of meningococcal disease is bacterial culture of *N. meningitidis* from a sterile site (e.g., blood or CSF). Meningococcal disease may also be diagnosed through detection of *N. meningitidis* with PCR assay. PCR testing can be a useful supplement to culture, particularly when a patient was treated with antibiotics prior to specimen collection. However, most assays do not determine serogroup. When using PCR testing, laboratories should perform simultaneous culture and use validated, specific, real-time PCR

assays capable of detecting and differentiating meningococcal serogroups. Otherwise, additional steps need to be taken, including performing a reflex culture or, at a minimum, retaining a clinical specimen for further testing at the Maine Health and Environmental Testing Laboratory (HETL).

HETL can perform culture and grouping for *N. meningitidis*. Culture can be performed on blood, CSF, or synovial fluid specimens. If CSF is collected, take care to avoid contamination with blood; a minimum of 0.5mL is needed. If culture was performed and *N. meningitidis* was identified at a commercial or hospital laboratory, the isolate must be sent to HETL for grouping. For additional information on sending specimen and/or isolates to HETL for testing please see the [laboratory submission information sheet \(LSIS\)](#).

Health care providers should initiate prompt transmission-based precautions (e.g., droplet precautions) for those suspected or confirmed with *N. meningitidis*.

U.S. CDC: Increase in Invasive Serogroup Y Meningococcal Disease in the United States

Summary

The Centers for Disease Control and Prevention (U.S. CDC) is issuing this Health Alert Network (HAN) Health Advisory to alert healthcare providers to an increase in invasive meningococcal disease, mainly attributable to *Neisseria meningitidis* serogroup Y (Figure 1). In 2023, 422 cases were reported in the United States, the highest annual number of cases reported since 2014. As of March 25, 2024, 143 cases have been reported to U.S. CDC for the current calendar year, an increase of 62 cases over the 81 reported as of this date in 2023. A specific meningococcal strain, sequence type (ST) 1466, is responsible for most (101 of 148, 68%) serogroup Y cases with available sequence type data that were reported across the United States in 2023. Cases caused by this strain are disproportionately occurring in people ages 30–60 years (65%), Black or African American people (63%), and people with HIV (15%). In addition, most cases of invasive meningococcal disease caused by ST-1466 in 2023 had a clinical presentation other than meningitis: 64% presented with bacteremia, and at least 4% presented with septic arthritis. Of 94 patients with known outcomes, 17 (18%) died; this case-fatality rate is higher than the historical case fatality rate of 11% reported for serogroup Y cases in 2017–2021.

Healthcare providers should

- 1) **have a heightened suspicion for meningococcal disease, particularly among populations disproportionately affected by the current increase,**
- 2) **be aware that patients may present without symptoms typical of meningitis, and**
- 3) **ensure that all people recommended for meningococcal vaccination, including people with HIV, are up to date for meningococcal vaccines.**

Background

[Meningococcal disease](#), caused by the bacterium *Neisseria meningitidis*, is a rare but severe illness with a case-fatality rate of 10–15% even with appropriate antibiotic treatment. Meningococcal disease most often presents as meningitis, with symptoms that may include fever, headache, stiff neck, nausea, vomiting, photophobia, or altered mental status; or as meningococcal bloodstream infection, with symptoms that may include fever and chills, fatigue, vomiting, cold hands and feet, severe aches and pains, rapid breathing, diarrhea, or, in later stages, a dark purple rash. While initial symptoms of meningococcal disease can at first be non-specific, they worsen rapidly, and the disease can become life-threatening within hours. Immediate [antibiotic treatment](#) for meningococcal disease is critical. Survivors may experience long-term effects such as deafness or amputations of the extremities.

Of the six *N. meningitidis* serogroups — A, B, C, W, X, and Y — responsible for most meningococcal disease worldwide, the four serogroups B, C, W, and Y circulate in the United States. Vaccines against serogroups A, C, W, Y (MenACWY) and serogroup B (MenB) are available in the United States. [MenACWY vaccines are routinely](#)


[recommended](#) for adolescents and for people with other risk factors or underlying medical conditions, including HIV.

Across the United States, 101 ST-1466 cases were reported in 2023. This number is expected to increase with additional laboratory testing data. Cases of invasive meningococcal disease caused by this strain occurred in both males (65%) and females (35%) and disproportionately occurred in people ages 30–60 years (65%), Black or African American people (63%), and people with HIV (15%). In addition, most cases of invasive meningococcal disease caused by ST-1466 had a clinical presentation other than meningitis: 64% presented with bacteremia, and at least 4% presented with septic arthritis. Of 94 patients with known outcomes, 17 (18%) died; this case-fatality rate is higher than the historical case-fatality rate of 11% reported for serogroup Y cases in 2017–2021.

The serogroup Y ST-1466 strain has contributed to [previously reported increases](#) in meningococcal disease in people with HIV. Based on updated surveillance data, 24 ST-1466 cases have now been reported in people with HIV in 2022–2023; only four were previously vaccinated with MenACWY and none were up to date on recommended doses. To date, no other ST-1466 cases have been identified in people who previously received MenACWY vaccine.

Serogroup Y ST-1466 isolates tested to date have been susceptible to all first-line antibiotics recommended for treatment and prophylaxis. This strain is distinct from [ciprofloxacin-resistant serogroup Y strains that are also circulating in the United States](#) and that are disproportionately affecting Hispanic individuals.

Figure 1: Trends in meningococcal disease incidence per 100,000 population, by serogroup—United States, 2006–2023. Incidence of *Neisseria meningitidis* serogroup Y is shown in green. Source: National Notifiable Diseases Surveillance System, with additional serogroup data from Active Bacterial Core surveillance (ABCs) and state health departments. 2022 and 2023 data are preliminary.



Recommendations for Health Care Providers

- Maintain a heightened suspicion for invasive meningococcal disease and start immediate [antibiotic treatment](#) for persons with suspected meningococcal disease. Blood and cerebrospinal fluid (CSF) cultures are indicated for patients with suspected meningococcal disease [1].
- For all suspected or confirmed *N. meningitidis* patients use standard and transmission-based precautions (droplet) until 24 hours after initiation of effective therapy.
- Recognize that invasive meningococcal disease may affect people of any age or demographic group.
 - Current increases in disease are disproportionately affecting people ages 30–60 years, Black or African American people, and people with HIV.
- Be aware that patients with invasive meningococcal disease may present with bloodstream infection or septic arthritis and **without** symptoms typical of meningitis (e.g., headache, stiff neck).
- Ensure that all people [recommended for meningococcal vaccination](#) are up to date for meningococcal vaccines.

- All 11–12 year-olds should receive a MenACWY vaccine. Since protection wanes, U.S. CDC recommends a booster dose at age 16 years.
- For people at increased risk due to medical conditions (e.g., with HIV), recommended vaccination includes a 2-dose primary MenACWY series with booster doses every 3–5 years, depending on age.
- Immediately notify Maine CDC at 1-800-821-5821 about any suspect or confirmed cases of invasive meningococcal disease.
- Perform a review to identify if there were any exposed persons to confirmed positive patient(s).
- Consult with Maine CDC for any questions about meningococcal disease treatment or contact prophylaxis, including any changes based on local meningococcal resistance patterns.

Recommendations for the Public

- Seek medical attention immediately if you or your child develops [symptoms of meningococcal disease](#):
 - Symptoms of meningitis may include fever, headache, stiff neck, nausea, vomiting, photophobia, or altered mental status.
 - Symptoms of meningococcal bloodstream infection may include fever and chills, fatigue, vomiting, cold hands and feet, severe aches and pains, rapid breathing, diarrhea, or, in later stages, a dark purple rash.
 - While symptoms of meningococcal disease can at first be nonspecific, they worsen rapidly, and the disease can become life-threatening within hours.
- Talk to your health care provider about [meningococcal vaccines](#) that may be recommended for you and your household or family members, including any recommended booster doses.

For More Information

- Health care providers
 - [Clinical information | Meningococcal Disease | U.S. CDC](#)
 - [Meningococcal Vaccination: Information for Healthcare Professionals | U.S. CDC](#)
 - [U.S. CDC: Type and Duration of Precautions Recommended for Selected Infections and Conditions](#)
- Everyone
 - [Signs and Symptoms | Meningococcal Disease | U.S. CDC](#)
 - [Meningococcal Vaccination | U.S. CDC](#)
 - Visit [CDC-INFO](#) or call CDC-INFO at 1-800-232-4636

References

1. American Academy of Pediatrics. Summaries of infectious diseases: meningococcal infections. [Section 3]. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red book: 2021–2024 report of the Committee on Infectious Diseases. Itasca, IL: American Academy of Pediatrics; 2021:519–32.
2. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. *MMWR Recomm Rep* 2020;69(No. RR-9):1–41. DOI: <http://dx.doi.org/10.15585/mmwr.rr6909a1>
3. Rubis AB, Howie RL, Marasini D, Sharma S, Marjuki H, McNamara LA. Notes from the Field: Increase in Meningococcal Disease Among Persons with HIV — United States, 2022. *MMWR Morb Mortal Wkly Rep* 2023;72:663–664. DOI: <http://dx.doi.org/10.15585/mmwr.mm7224a4>